← All trials
NCT06632977
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2024
- Primary completion
- Apr 11, 2030
- Completion date
- Oct 11, 2034
- First posted
- Oct 9, 2024
- Last posted
- Oct 9, 2024
- Enrollment
- 474
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- National Cancer Institute (NCI)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.